Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Questcor Pharmaceuticals

Questcor Pharmaceuticals

Provider of prescription drugs for the treatment of rare central nervous system and inflammatory disorders. The company's primary drug is H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of various diseases and disorders. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. H.P. Acthar Gel H.P. Acthar Gel is a natural source, highly purified preparation of the adrenal corticotropin hormone (ACTH).

Formerly Known As
Ribogene, Cypros Pharmaceutical
Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • 1300 North Kellogg Drive
  • Suite D
  • Anaheim, CA 92807
  • United States

+1 (714) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Questcor Pharmaceuticals’s full profile, request a free trial.

Questcor Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 15-Aug-2014 $5.79B 000.00 00.000 Completed Generating Revenue
6. IPO 06-Dec-2006 000.00 000.00 000.00 Completed Generating Revenue
5. Corporate 13-Dec-2001 00.000 000.00 00.000 Completed Generating Revenue
4. Corporate 01-Aug-2001 000 0000 Completed Generating Revenue
3. Corporate 29-Mar-2001 00.00 000 000.00 Completed Generating Revenue
2. Early Stage VC $6.5M Completed Generating Revenue
1. IPO 01-Nov-1992 $6.5M $6.5M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Questcor Pharmaceuticals Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
UCB Formerly PE-Backed Brussels, Belgium 0000 00000 000000 - 000 00000
00000000 000000000 Formerly VC-backed Allschwil, Switzerland 0000 00000 000000&0 00000
To view this company’s complete list of competitors, request access »

Questcor Pharmaceuticals Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 18-Jan-2013 000000000000000000 000.00 Other Pharmaceuticals and Biotechnology 000 000000
00000000 17-Jun-2003 000000000000000000 000.00 Pharmaceuticals 0000000 000000000
RiboGene 17-Nov-1999 Merger/Acquisition Drug Delivery
To view this company’s complete investment and acquisition history, request access »

Questcor Pharmaceuticals Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 18-Jan-2013 000000000000000000 000.00 Completed
  • 00000000 000000000
Nascobal 17-Jun-2003 Merger/Acquisition 000.00 Completed
To view this company’s complete exits history, request access »

Questcor Pharmaceuticals Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Biobrit Venture Capital Minority 000 0000 000000 0
Montreux Equity Partners Growth/Expansion Minority 000 0000 000000 0
Sigma Tau Finanziaria Corporation Minority 000 0000 000000 0
Signet Healthcare Partners Growth/Expansion Majority 000 0000 000000 0

Questcor Pharmaceuticals Executive Team (11)

Name Title Board
Dave Medeiros Executive Vice President & Chief Technology Officer
David Pharm Ph.D Chief Scientific Officer
Gregory Liposky Vice President, Contract Manufacturing
Charles Casamento President
David Young Ph.D Chief Scientific Officer

6 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

Questcor Pharmaceuticals Board Members (9)

Name Representing Role Since Contact
G. Kelly Martin Self Board Member 000 0000
Louis Silverman Self Board Member & Advisor 000 0000
Scott Whitcup MD Self Board Member 000 0000
Stephen Farrell Self Board Member 000 0000
Virgil Thompson JD Self Chairman 000 0000

4 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »